Themis Bioscience GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Themis Bioscience GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C0495
◆発行会社(調査会社):GlobalData
◆発行日:2018年7月
◆ページ数:21
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:オーストリア
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Themis Bioscience GmbH (Themis Bioscience) is a biotechnology company that develops prophylactic vaccines for emerging tropical infections. The company develops emerging and specialist indications and vaccines from preclinical to late-stage clinical development phases. It develops novel vaccine candidates using its proprietary Themaxyn vaccine platform with a vaccine vector system, loaded with antigens from a variety of non – infectious and infectious targets. Themis Bioscience develops innovative vaccine candidates for infectious diseases such as dengue, chikungunya and yellow fever virus. The company markets its products in Austria and abroad. Themis Bioscience is headquartered in Vienna, Austria.

Themis Bioscience GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Themis Bioscience GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
Themis Bioscience Raises USD12 Million in Series C Venture Financing 10
Themis Bioscience Secures USD10.58 Million in Series B Funding Round 11
Themis Bioscience Raises USD7.8 Million in Series B Financing 12
Partnerships 13
Themis Bioscience Enters into Partnership with CEPI 13
Themis Bioscience GmbH – Key Competitors 14
Themis Bioscience GmbH – Key Employees 15
Themis Bioscience GmbH – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
Feb 26, 2018: Themis Establishes Scientific Advisory Board of Experts in Virology and Vaccine Development 17
Product News 19
06/05/2017: NIAID-Sponsored Trial of Experimental Chikungunya Vaccine Begins 19
Clinical Trials 20
Apr 11, 2017: Zika Virus: Themis Bioscience Initiates Worldwide First Study With Live Attenuated Recombinant Vaccine 20
Appendix 21
Methodology 21
About GlobalData 21
Contact Us 21
Disclaimer 21

List of Tables
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Themis Bioscience GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Themis Bioscience GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 9
Themis Bioscience Raises USD12 Million in Series C Venture Financing 10
Themis Bioscience Secures USD10.58 Million in Series B Funding Round 11
Themis Bioscience Raises USD7.8 Million in Series B Financing 12
Themis Bioscience Enters into Partnership with CEPI 13
Themis Bioscience GmbH, Key Competitors 14
Themis Bioscience GmbH, Key Employees 15

List of Figures
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Themis Bioscience GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8

★海外企業調査レポート[Themis Bioscience GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Avery Dennison Corporation (AVY):企業の財務・戦略的SWOT分析
    Avery Dennison Corporation (AVY) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and wea …
  • Repro-Med Systems Inc (REPR):企業の財務・戦略的SWOT分析
    Summary Repro-Med Systems Inc (RMS) is a medical device company that develops and manufactures home and specialty infusion solutions. The company's products include syringe infusion system, subcutaneous safety needle sets, precision flow rate tubing, and hand held medical suction products. It offers …
  • GDS Holdings Ltd (GDS):企業の財務・戦略的SWOT分析
    GDS Holdings Ltd (GDS) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses an …
  • Arena Energy LP:石油・ガス:M&Aディール及び事業提携情報
    Summary Arena Energy Lp (Arena) operates as an oil and gas exploration company. It is engaged in developing and exploring of oil and gas in Gulf of Mexico. It identifies and develops investment opportunities in the Gulf of Mexico Shelf. It is also involved in drilling and off-shore activities. The c …
  • NSK Ltd (6471):企業の財務・戦略的SWOT分析
    NSK Ltd (6471) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the po …
  • Parity Group plc (PTY):企業の財務・戦略的SWOT分析
    Summary Parity Group plc (Parity) is a technology company that offers professional recruitment, IT solutions and consultancy services. The company’s technology solutions include business intelligence, database analytics and development; IT consulting and application management support.The company pr …
  • Inspire Medical Systems Inc-医療機器分野:企業M&A・提携分析
    Summary Inspire Medical Systems Inc (Inspire) is a medical device company that manufactures and markets healthcare implants. The company provides implanted neurostimulation device. Its product is used for treatment of obstructive sleep apnea. Inspire uses neurostimulation technologies. The company’s …
  • Vertex Pharmaceuticals Inc (VRTX):製薬・医療:M&Aディール及び事業提携情報
    Summary Vertex Pharmaceuticals Inc (Vertex) is a biotechnology company that carries out the discovery, development and commercialization of transformative drugs for the treatment of serious and life-threatening diseases. The company product portfolio includes Orkambi (ivacaftor/lumacaftor) and Kalyd …
  • Westwater Resources, Inc.:企業の戦略・SWOT・財務情報
    Westwater Resources, Inc. - Strategy, SWOT and Corporate Finance Report Summary Westwater Resources, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service …
  • Brigham and Women’s Hospital:企業のM&A・事業提携・投資動向
    Brigham and Women's Hospital - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Brigham and Women's Hospital Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, detailed reports on mergers and a …
  • MolMed SpA (MLM):企業の財務・戦略的SWOT分析
    Summary MolMed SpA (Molmed) is a biotechnology company which offers research, development, manufacturing and clinical validation of novel anticancer therapies. Its pipeline antitumour products include Zalmoxis (TK), a cell based therapy enabling bone marrow transplants donors for the treatment of hi …
  • Factor Therapeutics Ltd (FTT):医療機器:M&Aディール及び事業提携情報
    Summary Factor Therapeutics Ltd (FTL), formerly Tissue Therapies Ltd, is a developer of wound care therapeutics. The company develops treatments for acute and chronic wound healing applications such as chronic skin ulcers and burns. Its lead therapeutic candidate, VF-001 is a targeted growth factor …
  • N4 Pharma Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary N4 Pharma Ltd (n4 Pharma), a subsidiary of N4 Pharma Plc, is a drug reformulation company. The company develops and out licensing of new versions of existing high value drugs with an unmet commercial or medical need. Its proprietary platform technology, Cocrys and Nuvac, focus on improving t …
  • Klockner Pentaplast GmbH & Co. KG:企業の戦略・SWOT・財務情報
    Klockner Pentaplast GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report Summary Klockner Pentaplast GmbH & Co. KG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, pro …
  • Kura Oncology Inc (KURA):企業の財務・戦略的SWOT分析
    Summary Kura Oncology Inc (Kura Oncology) is a clinical-stage biopharmaceutical company that discovers and develops therapeutics for the treatment of solid tumors and blood cancers. The company’s lead drug candidate Tipifarnib, an inhibitor of farnesyl transferase, an oral investigational drug candi …
  • Al Rajhi Banking & Investment Corp (1120):企業の財務・戦略的SWOT分析
    Al Rajhi Banking & Investment Corp (1120) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strength …
  • ADT LLC:戦略・SWOT・企業財務分析
    ADT LLC - Strategy, SWOT and Corporate Finance Report Summary ADT LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, pr …
  • Lenovo Group Limited:企業の戦略・SWOT・財務情報
    Lenovo Group Limited - Strategy, SWOT and Corporate Finance Report Summary Lenovo Group Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings …
  • Spinneys Dubai LLC:企業の戦略・SWOT・財務分析
    Spinneys Dubai LLC - Strategy, SWOT and Corporate Finance Report Summary Spinneys Dubai LLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Mediq NV:製薬・医療:M&Aディール及び事業提携情報
    Summary Mediq NV (Mediq) is a provider of medical devices, pharmaceuticals and related care services. It offers these services directly to people’s homes (direct), through professional healthcare customers such as hospitals and care institutions (institutional), through wholesalers or through Mediq …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆